Current share price $3.55. Part of this, $2.75 (A1) ($3.50 later this year) belongs to drug NV07a. See item 2.1. of that post. Cash approx. 32 cents (A2).
This is a conservatively valued component.
2. Item 2.4 refers to "Isoflavones" and a small part of this, "the Soy Isoflavones" is part of the total share price. This part=$1.50 (case B) and based on a P/E of 20 and 97.5 mill shares is only $7.31 mill.
I consider this to be very conservative, mentioning has been made of $20-$25 mil. Assume it is 3*$7.31 mill. -See above. In that case the share price component will be 3*$1.50= $4.50 (case C).
The Patent needs enforcing of course but as Dupont is already paying milestone payments, this may not necessarily be a problem.
3. Summary: Item 1-See (A1), NV07a: $2.75. See (A2): Cash: 32 cents Case (B): $1.50 Case (C): $4.50
Therefore, if case B applies, the share price should be $2.75+$0.32+$1.50= **$4.57**
If case C applies, then the share price ought to be $2.75+$0.32+$4.50= **$7.57**
And this is for 2 components only and compares with the current **$3.55** share price.
4. These data exclude the possibly very important patents for Isoflavones (up to $ 9.30 per share, if enforced) to come, as well as an important possible Patent for Promensil.
It also excludes drug Phenoxodiol, the trials, the important upcoming drug NV04A-some trials to come, drug NV050633 and others.
Excluded are the value of other patents and the OTC products.
Those are my opinions.
Halcyon Disclaimer: Outcomes may be different than envisaged. Readers will buy, hold or sell NRT at their own risk.
NRT Price at posting:
0.0¢ Sentiment: None Disclosure: Held